ALMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alumis Inc (ALMS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong analyst ratings, positive clinical trial results, insider buying trends, and promising growth potential in the psoriasis treatment market outweigh the short-term technical indicators and financial setbacks. The SwingMax signal further supports a buy decision.
The MACD is negatively contracting, RSI is neutral at 60.072, and moving averages are converging, indicating no strong trend. The stock is trading near its resistance level (R1: 26.208) with a pivot at 24.534. Short-term technicals are neutral to slightly bullish.
Insider buying increased by 586.17% over the last month.
Strong analyst ratings with price targets ranging from $32 to $50, reflecting confidence in the company's lead asset envudeucitinib.
Positive Phase 3 clinical trial results for envudeucitinib in psoriasis.
SwingMax signal on 2026-03-26 with a 1.71% price increase since then.
Financial performance shows a reduced net loss but still negative EPS (-0.
and net income (-$92.93M) for Q4
Revenue for fiscal year 2025 fell short of market expectations.
Pre-market and post-market price changes indicate slight downward pressure.
Alumis reported a reduced net loss of $243.3M for FY 2025, an improvement from $294.2M in 2024. Revenue for FY 2025 was $24.05M, missing expectations by $0.23M. Q4 2025 revenue was flat YoY, while EPS dropped by 48.85% YoY. The company holds $308.5M in cash and marketable securities, supported by a $300M upsized public offering.
Analysts are overwhelmingly positive on ALMS, with multiple firms initiating or maintaining Buy/Strong Buy ratings and raising price targets. The highest price target is $50, and the lowest is $32, reflecting confidence in the company's potential to capture market share in psoriasis treatment.
